OR WAIT null SECS
October 16, 2017
Dow’s portfolio of solutions for pharmaceutical applications now includes products from Dow Corning’s silicone technology platform.
October 14, 2017
Samsung BioLogics’ second facility adds 152,000 L of mAb drug substance capacity.
October 13, 2017
The committee has voted unanimously to approve Spark Therapeutics’ gene therapy candidate, Luxturna (voretigene neparvovec), for treating a genetically inherited blindness.
October 12, 2017
The companies have entered into a strategic collaboration to establish a new cell therapy and regenerative medicine manufacturing platform, which includes a new manufacturing facility in Belgium.
October 11, 2017
BARDA has entered a $12-million contract with biopharmaceutical firm Achaogen for the late-stage development of an antibiotic against resistant bacteria, and as a potential treatment for biowarfare agents.
Johnson & Johnson’s Janssen Sciences Ireland UC will invest more than EUR 300 million (US$355 million) to expand manufacturing capacity for biologic medicines at its Ireland facility.
October 04, 2017
Compared to traditional drug discovery approaches, drug repurposing, repositioning, and rescue can be faster and cheaper.
Indena is completing the construction of a new GMP kilolab for highly potent APIs.
October 02, 2017
Sartorius begins building a new, EUR 30-million (US$35.2 million) Cell Culture Technology Center in Ulm, Germany.
CDMOs have established strategies for handling new chemical entities with unknown biological activity.